000109479 001__ 109479
000109479 005__ 20230519145456.0
000109479 0247_ $$2doi$$a10.3390/jpm11121260
000109479 0248_ $$2sideral$$a125694
000109479 037__ $$aART-2021-125694
000109479 041__ $$aeng
000109479 100__ $$aNavarra-Ventura G.
000109479 245__ $$aVirtual reality-based early neurocognitive stimulation in critically ill patients: A pilot randomized clinical trial
000109479 260__ $$c2021
000109479 5060_ $$aAccess copy available to the general public$$fUnrestricted
000109479 5203_ $$aThis study focuses on the application of a non-immersive virtual reality (VR)-based neurocognitive intervention in critically ill patients. Our aim was to assess the feasibility of direct outcome measures to detect the impact of this digital therapy on patients’ cognitive and emotional outcomes. Seventy-two mechanically ventilated adult patients were randomly assigned to the “treatment as usual” (TAU, n = 38) or the “early neurocognitive stimulation” (ENRIC, n = 34) groups. All patients received standard intensive care unit (ICU) care. Patients in the ENRIC group also received adjuvant neurocognitive stimulation during the ICU stay. Outcome measures were a full neuropsychological battery and two mental health questionnaires. A total of 42 patients (21 ENRIC) completed assessment one month after ICU discharge, and 24 (10 ENRIC) one year later. At onemonth follow-up, ENRIC patients had better working memory scores (p = 0.009, d = 0.363) and showed up to 50% less non-specific anxiety (11.8% vs. 21.1%) and depression (5.9% vs. 10.5%) than TAU patients. A general linear model of repeated measures reported a main effect of group, but not of time or group–time interaction, on working memory, with ENRIC patients outperforming TAU patients (p = 0.008, ¿p2 = 0.282). Our results suggest that non-immersive VR-based neurocognitive stimulation may help improve short-term working memory outcomes in survivors of critical illness. Moreover, this advantage could be maintained in the long term. An efficacy trial in a larger sample of participants is feasible and must be conducted. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
000109479 536__ $$9info:eu-repo/grantAgreement/ES/MICINN/IPT-300000-2010-13
000109479 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000109479 590__ $$a3.508$$b2021
000109479 592__ $$a0.757$$b2021
000109479 594__ $$a1.8$$b2021
000109479 591__ $$aMEDICINE, GENERAL & INTERNAL$$b69 / 172 = 0.401$$c2021$$dQ2$$eT2
000109479 593__ $$aMedicine (miscellaneous)$$c2021$$dQ2
000109479 591__ $$aHEALTH CARE SCIENCES & SERVICES$$b42 / 109 = 0.385$$c2021$$dQ2$$eT2
000109479 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000109479 700__ $$aGomà G.
000109479 700__ $$aHaro C.
000109479 700__ $$aJodar M.
000109479 700__ $$aSarlabous L.
000109479 700__ $$0(orcid)0000-0002-1462-4880$$aHernando D.
000109479 700__ $$0(orcid)0000-0003-1272-0550$$aBailón R.$$uUniversidad de Zaragoza
000109479 700__ $$aOchagavía A.
000109479 700__ $$aBlanch L.
000109479 700__ $$aLópez-Aguilar J.
000109479 700__ $$aFernández-Gonzalo S.
000109479 7102_ $$15008$$2800$$aUniversidad de Zaragoza$$bDpto. Ingeniería Electrón.Com.$$cÁrea Teoría Señal y Comunicac.
000109479 773__ $$g11, 12 (2021), 1260 [14 pp]$$pJ. pers. med.$$tJournal of Personalized Medicine$$x2075-4426
000109479 8564_ $$s1359148$$uhttps://zaguan.unizar.es/record/109479/files/texto_completo.pdf$$yVersión publicada
000109479 8564_ $$s2768245$$uhttps://zaguan.unizar.es/record/109479/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000109479 909CO $$ooai:zaguan.unizar.es:109479$$particulos$$pdriver
000109479 951__ $$a2023-05-18-14:50:55
000109479 980__ $$aARTICLE